HUTCHMED Shares Climb 4% on Positive Phase III Lung Cancer Trial Results

Key Facts

In a move reflecting significant progress in the global biotechnology sector, HUTCHMED announced positive top-line results from its Phase III SAFFRON study of savolitinib. According to reports, shares rose 4% after the trial demonstrated the drug's efficacy when used in combination with AstraZeneca's Tagrisso for patients with non-small cell lung cancer. The study specifically targeted patients whose condition had worsened despite previous treatments, validating the combination therapy as a viable clinical option.

These results strengthen the collaboration between HUTCHMED and AstraZeneca PLC, as the combination therapy was tested against specific genetic mutations in cancer patients. Per market data, AstraZeneca (AZN) shares closed at $156.91 in New York, while its London-listed shares (AZN.L) closed at 11,562 pence on August 17, 2026. This clinical milestone is viewed as a key step toward potential global regulatory submissions and future commercialization.

Investors are currently monitoring AstraZeneca's price levels following its close at $156.91 (close August 17, 2026), with the stock maintaining a range between a day low of $155.78 and a high of $157.26. While the upcoming economic calendar shows no direct pharmaceutical catalysts in the next seven days, market attention remains fixed on the timeline for regulatory filings following the successful SAFFRON trial outcomes.